Magnesium and Associated Minerals: A Clinical Guide to Supplementation

1. History and Context of Magnesium in Medicine

Magnesium's clinical history spans more than two centuries, from its identification as a chemical element to its current status as one of the most widely sold dietary supplements in the United States. Understanding this arc helps contextualize the evidence base — which ranges from robust (IV magnesium in eclampsia) to preliminary (magnesium threonate for cognition) — and grounds clinical decision-making appropriately.

2. Physiology: Why Magnesium Matters

Magnesium is not a peripheral micronutrient. It is a structural requirement for the fundamental biochemistry of the cell. Every major organ system depends on adequate magnesium, and the mechanisms by which deficiency produces pathology are now well characterized at the molecular level.

Cellular Biochemistry

Magnesium serves as an obligate cofactor in more than 300 enzymatic reactions. Among the most fundamental: ATP does not function as an energy substrate in its free ionic form — it must complex with Mg²⁺ (forming Mg-ATP) to be recognized by ATPases and kinases. This means that virtually every energy-dependent process in the cell — including membrane ion pumping, protein phosphorylation, and muscle contraction — is directly magnesium-dependent. Magnesium also participates in DNA and RNA synthesis and repair, acting as a cofactor for DNA polymerase and serving as a stabilizing counterion for the negatively charged phosphate backbone of nucleic acids. Protein synthesis at the ribosomal level likewise requires Mg²⁺ for ribosome integrity.

NMDA Receptor Gating: Relevance to Psychiatry and Pain

One of magnesium's most clinically significant neurological roles is the voltage-dependent block of the N-methyl-D-aspartate (NMDA) receptor ion channel. At resting membrane potentials, Mg²⁺ physically occludes the NMDA channel pore, preventing calcium influx even in the presence of glutamate and glycine co-agonists. This block is relieved only when the postsynaptic membrane is sufficiently depolarized, making NMDA receptor activation coincident with adequate membrane depolarization — a mechanism central to synaptic plasticity and long-term potentiation.

The psychiatric implications are substantial. Reduced magnesium availability attenuates this physiological block, resulting in excessive NMDA receptor activity. This has been proposed as a mechanism contributing to depressive neurophysiology, anxiety, and central sensitization states (including fibromyalgia and chronic pain syndromes). The convergence of magnesium deficiency with NMDA overactivity provides a plausible mechanistic link to the clinical observations of mood disorders in hypomagnesemic patients. Ketamine's antidepressant mechanism — NMDA antagonism — operates on the same receptor system.

HPA Axis Regulation

Magnesium modulates the hypothalamic-pituitary-adrenal (HPA) axis at multiple levels. It inhibits ACTH secretion from the anterior pituitary and reduces the sensitivity of the adrenal cortex to ACTH stimulation. In animal models, dietary magnesium deficiency produces HPA hyperactivation with elevated basal and stress-induced corticosterone. This creates a biologically plausible link between subclinical magnesium deficiency and the dysregulated cortisol responses observed in major depression and anxiety disorders.

Neurotransmitter Regulation

Beyond NMDA gating, magnesium modulates GABA-A receptor function, appears to influence serotonin synthesis (via tryptophan hydroxylase, a Mg-dependent enzyme), and reduces neuronal excitability by supporting the Na⁺/K⁺-ATPase that maintains resting membrane potential. The net effect of adequate magnesium is a buffering of excessive excitatory neurotransmission — consistent with its clinical associations with anxiety reduction and sleep promotion.

Cardiovascular Effects

Magnesium produces direct vasodilation through inhibition of calcium-mediated smooth muscle contraction — functionally acting as a physiological calcium channel antagonist. It supports endothelial nitric oxide production and reduces vascular reactivity. Its antiarrhythmic properties stem from stabilization of cardiac membrane potentials, prolongation of the refractory period, and blockade of calcium-dependent afterdepolarizations. These mechanisms underlie the clinical utility of IV magnesium in torsades de pointes and the association between dietary magnesium adequacy and lower cardiovascular event rates in epidemiological studies.

Bone Metabolism

Approximately 60% of total body magnesium resides in bone, where it is incorporated into the hydroxyapatite crystal lattice. Magnesium deficiency impairs osteoblast function, reduces bone quality (independent of calcium and vitamin D), and may increase fracture risk. Magnesium also influences PTH secretion and vitamin D activation — making its role in bone health interconnected with the broader calcium-vitamin D regulatory system.

Glucose and Insulin Signaling

Magnesium is required for insulin receptor tyrosine kinase activity and for the downstream intracellular signaling that enables glucose uptake. Intracellular magnesium deficiency impairs insulin receptor function, contributing to insulin resistance at the cellular level. Prospective cohort data and meta-analyses consistently show an inverse relationship between dietary magnesium intake and T2DM risk, with each 100 mg/day increment in intake associated with approximately a 15% reduction in diabetes risk in pooled analyses.

Systemic Inflammation

Magnesium deficiency activates the NF-κB pathway and promotes release of pro-inflammatory cytokines including IL-6, TNF-alpha, and CRP. This inflammatory phenotype is independent of obesity or metabolic syndrome and has been proposed as a mechanism linking dietary magnesium inadequacy to the elevated inflammatory markers observed in depression, cardiovascular disease, and metabolic syndrome.

Psychiatric Relevance: The Evidence Base

Multiple meta-analyses have found significant inverse associations between serum magnesium levels and risk of depression. A 2017 meta-analysis by Cheungpasitporn et al. found hypomagnesemia associated with approximately 1.5-fold increased odds of depression in cross-sectional studies. Animal models of dietary magnesium deficiency reliably produce anxiety-like and depression-like behavior that is reversible with repletion. Emerging research suggests adjunctive magnesium supplementation in bipolar disorder and anxiety disorders, though evidence remains preliminary for these specific indications. The mechanistic convergence — NMDA modulation, HPA regulation, neurotransmitter synthesis — provides biological plausibility that supports cautious clinical application pending further trial data.

3. Serum Magnesium: Testing and the "Normal" Problem

The routine clinical measurement of magnesium status is serum magnesium — and it is an inadequate biomarker for total body magnesium. Serum magnesium accounts for only approximately 1% of total body magnesium stores, with the remaining 99% distributed intracellularly across muscle (27%), soft tissue, and bone (60%). The serum compartment is tightly regulated; serum magnesium can remain within the reported normal range (0.75–0.95 mmol/L) even when intracellular magnesium is substantially depleted.

Limitations of Serum Measurement

A patient can have a normal serum magnesium and clinically significant intracellular magnesium deficiency, particularly following prolonged exposure to magnesium-depleting medications, chronic illness with poor dietary intake, or gastrointestinal malabsorption. More sensitive measures of magnesium status include red blood cell (RBC) magnesium — reflecting intracellular content — and 24-hour urinary magnesium excretion, which, when low (<1 mmol/day) in a hypomagnesemic patient, suggests inadequate dietary intake or absorption rather than renal wasting. These tests, though more physiologically meaningful, are infrequently ordered in clinical practice. The practical implication: clinical assessment must incorporate symptoms, dietary history, medication exposures, and comorbidities alongside the serum value.

Medications That Deplete Magnesium

• Loop diuretics (furosemide, bumetanide, torsemide): Inhibit NKCC2-mediated magnesium reabsorption in the thick ascending limb; among the most potent magnesiuric agents
• Thiazide diuretics: Increase urinary magnesium excretion; relevant in long-term hypertension management
• Proton pump inhibitors: FDA safety communication issued 2011 — PPI use for ≥1 year associated with hypomagnesemia; mechanism involves reduced intestinal magnesium absorption via TRPM6/7 channel downregulation
• Aminoglycosides (gentamicin, tobramycin): Nephrotoxic; impair renal tubular magnesium reabsorption
• Amphotericin B: Causes renal tubular dysfunction with significant urinary magnesium wasting; monitor closely during systemic antifungal treatment
• Cisplatin: Nephrotoxicity causes marked renal magnesium wasting; hypomagnesemia is a common complication of platinum-based chemotherapy
• Tacrolimus / cyclosporine: Calcineurin inhibitors impair TRPM6-mediated magnesium transport in the distal nephron
• Chronic alcohol: Dietary deficiency, GI losses, and renal wasting collectively produce severe hypomagnesemia in alcohol use disorder

Medical Conditions Associated with Depletion

• Type 2 diabetes mellitus: Osmotic diuresis from glucosuria increases urinary magnesium losses; and insulin resistance impairs cellular uptake
• Gastrointestinal malabsorption: Crohn's disease, celiac disease, and short bowel syndrome reduce intestinal magnesium absorption
• Alcoholism: Multifactorial depletion as described above
• Primary aldosteronism: Aldosterone increases urinary magnesium excretion
• Renal tubular disorders: Gitelman syndrome (SLC12A3 mutations) and Bartter syndrome cause obligatory renal magnesium wasting
• Hypokalemia and hypocalcemia: Frequently co-occur with hypomagnesemia; refractory hypokalemia that fails to correct with potassium supplementation is a classic sign of concurrent magnesium depletion

Symptoms of Hypomagnesemia

Mild-to-moderate deficiency may be asymptomatic or produce nonspecific symptoms: fatigue, muscle cramps, irritability, insomnia, anxiety, palpitations, and headache. More severe hypomagnesemia (serum <0.5 mmol/L) can produce tremors, hyperreflexia, tetany, and in severe cases, generalized seizures and ventricular arrhythmias. The symptom threshold is variable, particularly in patients with concurrent electrolyte disturbances.

4. Forms of Magnesium: Choosing the Right Formulation

The formulation of magnesium is not clinically interchangeable. Differences in elemental magnesium content, bioavailability, gastrointestinal tolerance, and tissue distribution — including potential blood-brain barrier penetration — have direct bearing on clinical outcomes. The ubiquity of magnesium oxide on pharmacy shelves belies its pharmacological limitations; selecting the appropriate form for the indication at hand is a meaningful clinical decision.

Magnesium Oxide

Magnesium oxide contains the highest elemental magnesium content by weight (approximately 60%), which is why it appears cost-effective on a milligram-per-milligram-elemental basis. However, its bioavailability is poor — estimated at less than 5% under most conditions. The majority of an oral oxide dose remains unabsorbed and exerts an osmotic laxative effect in the colon, which is its primary therapeutic utility (bowel preparation, constipation). For patients seeking systemic repletion — particularly for neurological, psychiatric, cardiovascular, or metabolic indications — magnesium oxide is not the appropriate choice. Despite this, it remains the dominant form in mass-market OTC supplements.

Magnesium Citrate

Magnesium citrate (approximately 16% elemental magnesium by weight) demonstrates meaningfully better bioavailability than oxide, estimated at approximately 25–30% in comparative studies. It is reasonably well tolerated at standard doses, with loose stools occurring if doses are excessive. Magnesium citrate has been used as a bowel preparation agent at high doses and as a general systemic supplement at lower doses. It is a reasonable first-line choice for general magnesium repletion when the more targeted forms are cost-prohibitive, and it has been studied in migraine prophylaxis.

Magnesium Glycinate (Bisglycinate)

Magnesium glycinate is a chelated form in which magnesium is bound to glycine via a coordinate covalent bond. This chelation confers two distinct advantages: superior bioavailability (estimates vary, but consistently higher than oxide; approximately 40–50% in comparative pharmacokinetic studies) and minimal laxative effect, because the chelated form is absorbed via peptide transporters in the small intestine rather than relying on passive diffusion. The glycine component itself carries pharmacological activity — glycine is an inhibitory neurotransmitter at glycinergic synapses and a co-agonist at the NMDA receptor, where it occupies the glycine-B site. Glycine supplementation has independently been associated with sleep-promoting effects in human trials. This dual activity makes glycinate the preferred form for neurological and psychiatric applications, including anxiety, insomnia, depression adjunct therapy, and migraine prophylaxis. It is also among the better-tolerated forms for long-term supplementation.

Magnesium L-Threonate (Magtein)

Magnesium L-threonate was developed at MIT (Liu et al., 2010) based on observations that threonate, a vitamin C metabolite, selectively enhances central nervous system magnesium levels in animal models by facilitating transport across the blood-brain barrier (BBB). In animal studies, magnesium threonate increases synaptic density, improves spatial and associative memory, and elevates cerebrospinal fluid magnesium more effectively than other forms. Human data are more limited but emerging: early trials suggest benefits for sleep latency, anxiety, and cognitive function in older adults. It remains the most expensive available form, carries the smallest elemental magnesium content per dose among major formulations, and requires ongoing clinical trial validation before strong efficacy claims can be made. For clinicians treating patients with specific neuropsychiatric or cognitive indications, it represents a reasonable premium option with a plausible mechanistic rationale.

Magnesium Malate

Bound to malic acid, magnesium malate has good bioavailability and the additional theoretical benefit of malic acid's role as an intermediate in the Krebs cycle — potentially supporting mitochondrial energy production in conditions characterized by cellular energy deficiency. Small studies have suggested utility in fibromyalgia and chronic fatigue-related muscle pain, likely via combined magnesium repletion and malic acid effects. It is well absorbed and generally well tolerated.

Magnesium Taurate

Magnesium taurate combines magnesium with taurine, an amino sulfonic acid with independent cardiovascular and neurological properties. Taurine modulates calcium channels, reduces blood pressure, and has antiarrhythmic properties — creating a pharmacological rationale for co-delivery with magnesium in cardiovascular contexts. Evidence specifically comparing taurate to other magnesium forms for clinical outcomes is limited; it is primarily distinguished by the potential additive cardiovascular benefit of taurine.

Magnesium Sulfate

Intravenous and intramuscular magnesium sulfate represent the highest-evidence form of magnesium in medicine. IV magnesium sulfate (4 g loading dose, 1–2 g/hour maintenance infusion) is the standard of care for eclampsia seizure prophylaxis and treatment. IV bolus administration (1–2 g over 5–20 minutes) is first-line for torsades de pointes regardless of magnesium level. A 2 g IV infusion is used adjunctively in acute severe asthma unresponsive to bronchodilators. Oral magnesium sulfate (Epsom salts) has very poor palatability and high osmotic laxative effect; its use is as a bowel preparation. Topical application (bath soaks, transdermal sprays) is widely marketed but absorption data are sparse and inconsistent; it should not be relied upon for systemic repletion.

Magnesium Chloride

Magnesium chloride has good bioavailability in oral form and is used in some topical preparations. Like magnesium sulfate, its topical absorption claims are not well-supported by high-quality pharmacokinetic data. Oral magnesium chloride is an acceptable form for systemic repletion with reasonable tolerability.

Clinical Decision: Threonate vs. Glycinate

For most psychiatric and neurological indications — anxiety, insomnia, depression adjunct, migraine — magnesium glycinate is the appropriate first-line recommendation based on established bioavailability, tolerability, dual glycine activity, and cost. Magnesium L-threonate is a reasonable alternative when the clinical focus is cognitive function, dementia-adjacent conditions, or when the patient has previously failed to respond to glycinate at adequate doses for neurological indications. The premium cost of threonate is a practical barrier that should be discussed with patients.

5. Clinical Indications and Dosing

Migraine Prophylaxis

Magnesium is among the few nutritional interventions with guideline-level support for migraine prevention. The American Academy of Neurology (AAN) assigns Level B evidence to magnesium supplementation for migraine prophylaxis based on multiple randomized controlled trials. Proposed mechanisms include inhibition of cortical spreading depression, reduction of NMDA-mediated hyperexcitability, and vasodilatory effects. Magnesium deficiency may be disproportionately prevalent in migraineurs. Doses studied range from 400–600 mg elemental magnesium daily. Magnesium citrate and oxide have been used in trials; glycinate is preferred clinically for tolerability. Particularly strong evidence exists for menstrual migraine, where cyclic hormonal shifts may worsen magnesium status.

Anxiety and Stress Response

Systematic reviews and meta-analyses support a modest but consistent anxiolytic effect of magnesium supplementation in patients with baseline deficiency or elevated stress. The mechanisms are mechanistically credible: NMDA blockade reduces excitotoxic neuronal firing, glycine co-agonism (in glycinate formulations) adds inhibitory tone, and HPA axis dampening reduces cortisol burden. Magnesium should be positioned as an adjunct — not a replacement for evidence-based anxiety treatment — but its excellent safety profile makes it a low-risk addition at 200–400 mg/day of elemental magnesium as glycinate.

Depression

The Tarleton et al. 2017 RCT (PLoS ONE) randomized 126 adults with mild-to-moderate depression to 248 mg elemental magnesium chloride daily vs. active control and found significant improvement in PHQ-9 scores within 6 weeks, with effects comparable to the control condition and a favorable side effect profile. This trial, while not large enough to establish magnesium as a stand-alone antidepressant, supports its adjunctive role particularly in patients on SSRIs or SNRIs who have had incomplete response, and in patients with documented low magnesium intake or subclinical deficiency. The mechanistic rationale — NMDA modulation, HPA normalization, serotonin synthesis support — is compelling.

Insomnia

Abbasi et al. (2012, Journal of the American Geriatrics Society) conducted a double-blind RCT of 500 mg magnesium daily in elderly adults with insomnia and found significant improvements in sleep efficiency, sleep onset latency, serum melatonin levels, and renin levels compared to placebo. The proposed mechanism involves magnesium's regulation of NMDA and GABA-A receptors, and its role in melatonin synthesis. Magnesium glycinate or threonate at 200–400 mg taken at bedtime represents a reasonable recommendation for patients with insomnia, particularly when pharmacological sleep aids are undesirable.

Restless Leg Syndrome

Magnesium 300 mg at bedtime has modest support from small open-label studies for reducing RLS symptoms. Before initiating magnesium for RLS, clinicians should exclude iron deficiency (the most common correctable cause), dopaminergic dysfunction, and medication-related causes (antihistamines, antidopaminergic agents). Magnesium may be a reasonable adjunctive measure but is not established as primary therapy.

Type 2 Diabetes Prevention and Metabolic Health

Meta-analyses including the Guerrero-Romero et al. work demonstrate that each 100 mg/day increment in dietary magnesium intake is associated with approximately a 15% reduction in T2DM incidence in prospective cohort studies. Supplementation trials in insulin-resistant patients have shown improvements in fasting glucose and insulin sensitivity. Magnesium supplementation is not a therapeutic substitute for lifestyle modification or glucose-lowering medications but may represent a meaningful adjunct in high-risk patients with documented dietary insufficiency.

Hypertension

A 2016 meta-analysis by Zhang et al. in Hypertension (37 trials, n=2,028) found that magnesium supplementation at a median dose of 368 mg/day reduced SBP by approximately 2 mmHg and DBP by approximately 1.8 mmHg. The effect size is modest and clinically adjunctive rather than therapeutic. Nevertheless, in patients with mild hypertension on lifestyle modification, magnesium supplementation represents a low-risk intervention worth considering, particularly when dietary intake is low.

Muscle Cramps

Evidence for magnesium in pregnancy-associated leg cramps is reasonably strong, with multiple RCTs showing benefit. Evidence for non-pregnancy cramps (nocturnal leg cramps in older adults) is more mixed; a 2017 Cochrane review found insufficient evidence to recommend routine magnesium supplementation for this indication. Nevertheless, given its safety profile, a therapeutic trial is not unreasonable in patients with frequent, distressing cramps and evidence of dietary insufficiency.

ADHD

Magnesium and vitamin B6 combination has been studied in pediatric and adult ADHD with mixed results. Some trials show improved attention and hyperactivity scores, but methodological quality is variable. Magnesium supplementation is not part of evidence-based ADHD management guidelines, though investigation into the role of nutritional deficiencies in ADHD continues.

Bipolar Disorder

Given magnesium's NMDA-modulating properties — mechanistically analogous in some respects to lithium and ketamine — there is theoretical interest in its role as an adjunct in bipolar disorder. Small studies and case reports suggest possible mood-stabilizing effects. Evidence is insufficient to support a clinical recommendation, but in patients with bipolar disorder who have documented magnesium deficiency, repletion is physiologically appropriate.

IV/IM Indications (Hospital-Based)

• Eclampsia / preeclampsia: IV magnesium sulfate 4 g loading dose over 20 minutes, then 1–2 g/hour continuous infusion; monitor patellar reflexes, respiratory rate, and urine output; therapeutic level 2–4 mmol/L
• Torsades de pointes: IV magnesium sulfate 1–2 g over 5–20 minutes; effective even in patients with normal serum magnesium
• Status asthmaticus: IV magnesium sulfate 2 g over 20 minutes adjunctively in severe acute asthma
• Severe hypomagnesemia (serum <0.5 mmol/L with symptoms): IV repletion preferred; 1–2 g IV over 1 hour, followed by ongoing infusion or transition to oral

6. Associated Minerals and Co-Factors

Magnesium does not act in isolation. Its absorption, cellular utilization, and clinical effects are modulated by several co-factors and competing cations that are relevant to prescribing decisions.

Zinc

Zinc and magnesium are frequently combined in supplement formulations ("ZMA" products being among the most commercially recognized). Zinc is an NMDA receptor modulator — it inhibits NMDA receptor activity at the Zn²⁺ binding site distinct from the magnesium channel block — creating theoretical complementarity. Zinc is also essential for immune function, testosterone biosynthesis, and wound healing. The RDA is 11 mg/day for men and 8 mg/day for women. Deficiency is common in the elderly, strict vegetarians (plant phytates reduce bioavailability), and individuals with alcohol use disorder or chronic diarrheal illness. An important caution: excessive zinc supplementation (above approximately 50 mg/day chronically) competitively inhibits copper absorption, leading to copper deficiency with potential neurological sequelae including myelopathy and peripheral neuropathy.

Boron

Boron is a trace element without an established RDA, though typical supplementation doses are 3–6 mg/day. Evidence suggests boron enhances intestinal magnesium absorption and reduces renal magnesium excretion, effectively improving magnesium retention. Boron also supports bone density (appears to reduce urinary calcium and magnesium loss), modulates estrogen and testosterone metabolism, and has emerging data suggesting cognitive benefits in deficient states. Dietary boron is found primarily in fruits, nuts, and vegetables; deficiency is more common in populations with low fruit and vegetable intake.

Vitamin B6 (Pyridoxine)

Pyridoxine is required for cellular magnesium uptake — B6 deficiency impairs the transport of magnesium into cells even when serum magnesium is adequate. B6 is also an indispensable cofactor in the synthesis of serotonin (from 5-HTP), dopamine (from L-DOPA), and GABA — making its status directly relevant to neuropsychiatric function. B6 deficiency is seen in individuals on isoniazid, oral contraceptives, and some anticonvulsants. Combined Mg + B6 formulations have been studied specifically in ADHD and anxiety. Clinicians must be aware of the established neurotoxicity of high-dose pyridoxine: supplemental doses consistently above 100 mg/day (some reports suggest as low as 50 mg/day with prolonged use) can produce sensory neuropathy. This risk is absent at the 10–25 mg doses common in combined Mg-B6 products, but patients using separate high-dose B6 supplements concurrently should be counseled.

Phosphorus

High phosphate intake — characteristic of Western diets rich in processed foods, carbonated beverages (phosphoric acid), and protein supplements — can complex with magnesium in the intestinal lumen to form insoluble magnesium phosphate salts, reducing magnesium absorption. Patients with high processed food intake may have impaired magnesium absorption that is not fully corrected by supplementation alone without dietary modification. Additionally, hyperphosphatemia in chronic kidney disease further impairs magnesium balance by altering the tubular handling of divalent cations.

7. Safety, Toxicity, and Dangers

Oral Safety and Tolerable Upper Intake Level

Oral magnesium from food sources has no established toxicity in healthy individuals with normal renal function; excess dietary magnesium is simply not absorbed. For supplemental magnesium, the National Institutes of Health Office of Dietary Supplements establishes a Tolerable Upper Intake Level (UL) of 350 mg/day of supplemental elemental magnesium for adults. This limit is based not on systemic toxicity but on the laxative threshold — doses above this level commonly produce osmotic diarrhea, particularly with poorly absorbed forms (oxide, sulfate). Nausea and abdominal cramping may also occur. Chelated forms (glycinate, threonate, malate) have better GI tolerance and may be used at higher doses with fewer GI adverse effects, though caution is still warranted in renal impairment.

Hypermagnesemia

Hypermagnesemia (serum Mg >1.1 mmol/L) is primarily a risk in patients with renal impairment who take oral magnesium supplements or receive IV magnesium. The kidney is the principal route of magnesium elimination; when GFR is reduced, magnesium accumulates. Clinicians should use oral magnesium supplementation with caution in patients with GFR <30 mL/min/1.73m², and avoid it or monitor closely in dialysis patients.

The progression of hypermagnesemia symptoms is predictable and follows serum levels:

• Mild (>1.1 mmol/L): Flushing, nausea, headache, fatigue
• Moderate (~2–3 mmol/L): Hypotension, bradycardia, decreased deep tendon reflexes (loss of patellar reflex is the first clinical sign of significant toxicity and should halt IV infusions immediately)
• Severe (~4–5 mmol/L): Respiratory depression, neuromuscular paralysis
• Critical (>6 mmol/L): Cardiac arrest, coma

Neonatal Hypermagnesemia

Neonates born to mothers who received IV magnesium sulfate for eclampsia or preterm labor tocolysis may exhibit hypermagnesemia at birth. Clinical findings include hypotonia, respiratory depression, and reduced feeding. Neonates should be monitored for these signs; management is supportive, and calcium gluconate can be administered for severe cases.

Drug Interactions

• Fluoroquinolones and tetracyclines: Magnesium chelates these antibiotics in the GI tract, reducing their absorption by up to 90%. Separate administration by at least 2 hours (magnesium taken 2 hours after or 6 hours before the antibiotic)
• Bisphosphonates (alendronate, risedronate): Same chelation mechanism; take bisphosphonate first thing in the morning on an empty stomach, withhold magnesium for at least 2 hours
• Neuromuscular blocking agents: IV magnesium potentiates both depolarizing (succinylcholine) and non-depolarizing neuromuscular blockers; anesthesia teams should be informed of IV magnesium use preoperatively
• CNS depressants: High-dose magnesium may have additive sedative effects; relevant primarily with IV administration
• Calcium channel blockers: Theoretical additive vasodilatory and hypotensive effects with IV magnesium; monitor blood pressure
• Digoxin: Hypomagnesemia increases digoxin toxicity risk; magnesium repletion is clinically important in digitalis toxicity with concurrent hypomagnesemia

Renal Insufficiency Guidance

GFR 30–60 mL/min: Oral supplementation generally safe at standard doses (200–400 mg elemental Mg/day) with periodic serum monitoring every 3–6 months. GFR <30 mL/min: Reduce dose substantially, avoid high-dose supplementation, and monitor serum magnesium monthly. Dialysis patients: Magnesium is dialyzable; dialysate magnesium concentration should be considered when managing supplementation needs.

8. Practical Prescribing Guidance

Selecting the Formulation

Match the formulation to the indication:

• Neurological/psychiatric indications (anxiety, insomnia, depression adjunct, migraine): Magnesium glycinate 200–400 mg elemental Mg/day; glycinate preferred for cost-effectiveness and dual glycine activity
• Cognitive or specific neuropsychiatric focus: Magnesium L-threonate if the patient can afford it and has tried glycinate without sufficient response; typical commercial dose provides ~144 mg elemental Mg/day
• Cardiovascular indications (hypertension adjunct): Magnesium citrate or taurate
• Gastrointestinal / bowel function: Magnesium oxide or sulfate (laxative effect intentional)
• Fibromyalgia / muscle fatigue: Magnesium malate
• Acute hospital indications: Magnesium sulfate IV/IM exclusively
• General dietary repletion on a budget: Magnesium citrate

When to Check Serum Magnesium

Order serum magnesium when: the patient is on loop or thiazide diuretics, PPIs for >12 months, aminoglycosides, cisplatin, or tacrolimus; when hypokalemia or hypocalcemia is present and refractory to supplementation; in patients with alcoholism, IBD, celiac, or short bowel syndrome; in ICU patients on admission; and whenever the clinical presentation includes unexplained muscle cramps, hyperreflexia, arrhythmias, or treatment-resistant depression/anxiety. Remember that a normal serum level does not exclude intracellular deficiency in high-risk clinical contexts.

When Serum Magnesium Is Insufficient

In patients with compelling clinical deficiency (symptoms, depleting conditions, depleting medications) and a normal serum magnesium, consider ordering RBC magnesium and/or 24-hour urinary magnesium excretion. A low urine magnesium with symptoms suggests dietary/absorptive deficiency; a high urine magnesium suggests renal wasting, which warrants nephrology evaluation to identify the underlying tubular disorder.

When to Refer

• Nephrology: Suspected renal tubular magnesium wasting (refractory hypomagnesemia with elevated urinary magnesium), GFR <30, dialysis patients
• Gastroenterology: Suspected malabsorptive etiology (IBD, celiac disease, short bowel syndrome) contributing to refractory hypomagnesemia
• Endocrinology: Primary aldosteronism; hypoparathyroidism-associated magnesium disturbance

Patient Education Principles

• Start low, go slow: Begin at half the target dose for 1–2 weeks to minimize GI adverse effects, then titrate upward
• Divide doses: Spreading the daily dose into two divided doses (e.g., morning and bedtime) reduces peak GI exposure and may improve total daily absorption
• Take with food: Food slows gastric emptying and may improve absorption and tolerance; exception — bedtime glycinate for sleep can be taken without food
• Separate from antibiotics and bisphosphonates: Counsel patients on the 2-hour rule explicitly
• Duration: In patients with ongoing depleting conditions (chronic diuretic use, IBD, PPIs), supplementation is likely to be long-term maintenance rather than a finite course
• Realistic expectations: For neuropsychiatric indications, effects on mood, sleep, and anxiety typically become apparent within 4–8 weeks of consistent use; migraine prevention requires a 3-month minimum trial